Direct compression of nortriptyline hydrochloride at tablet strengths equivalent to 10 mg, 25 mg, 50 mg, or 75 mg nortriptyline base requires handling the stoichiometric salt correction rather than assuming label claim equals API mass. The molecular weight of nortriptyline base is 263.38 g/mol, and the hydrochloride salt is 299.84 g/mol, yielding a conversion factor of 1.138. Consequently, the hydrochloride masses per tablet are 11.38 mg, 28.45 mg, 56.90 mg, and 85.35 mg for the four strengths. In a 250 mg tablet core, the API concentration therefore varies from approximately 4.55% w/w for the 10 mg base claim to 34.14% w/w for the 75 mg base claim. This concentration span changes flow and compressibility behavior across the dose range. The API is screened through a 0.5 mm stainless-steel mesh on a conical mill before blending. Bulk excipients are screened through the same mill to break soft agglomerates. Microcrystalline cellulose is added as a diluent in the range of 40% w/w to 80% w/w for lower strengths and 30% w/w to 60% w/w for the 75 mg strength. Pregelatinized starch is added as a disintegrant at 5% w/w to 10% w/w. Crospovidone is used as a secondary disintegrant at 2% w/w to 5% w/w. Colloidal silicon dioxide is added as a glidant at 0.2% w/w to 0.8% w/w. The pre-lubrication blend is mixed in a bin blender at 50% to 70% of vessel volume, typically at 10 rpm to 14 rpm for 150 to 300 revolutions. Magnesium stearate is added at 0.5% w/w to 1.0% w/w through a 0.3 mm screen, and the final blend is mixed for an additional 60 to 130 revolutions. Excessive lubricant contact time is a known production-scale failure because it can reduce tablet tensile strength and increase capping tendency at compression forces above 12 kN. The tablet press is operated with B tooling at 30 rpm to 60 rpm, and in-process weight control is conducted under 21 CFR 211.110. Blend uniformity is tested by HPLC using USP <621>. Finished-tablet content uniformity is assessed by USP <905>. Disintegration is tested by USP <701>, and dissolution is conducted under USP <711> with product-specific media and acceptance criteria. The terminal product is an immediate-release tablet intended for film coating.

What Changes When Roller Compaction Replaces Direct Compression for the 75 mg Strength?

At 75 mg base per tablet, the hydrochloride equivalent is 85.35 mg, and the high API fraction reduces the proportion of free-flowing diluent available to the formulation. The direct compression blend often shows flowability defects when the Carr index exceeds 25 or the mass flow rate through a 10 mm orifice is slower than 20 g/s. These limits are not pharmacopoeial but are used in process feasibility studies. When direct compression cannot hold weight variability below 2% RSD, roller compaction is introduced. The preblend is fed to a roller compactor with a 1.5 mm to 3.0 mm roll gap and a knurled roll surface. Hydraulic pressure is not fixed. The operator brackets pressure to achieve ribbon solid fraction between 0.60 and 0.75, measured by envelope density against true density. Undercompacted ribbons produce excessive fines and segregation. Overcompacted ribbons cause granule hardness high enough to delay disintegration. Ribbons are milled through a screen of 0.8 mm to 1.0 mm, and the granule fraction between 150 µm and 850 µm is used as the press feed. Fines below 150 µm are controlled below 20% w/w because they reintroduce flow and segregation risk. The granulation is lubricated with magnesium stearate at 0.5% w/w and compressed on a rotary press with B tooling. Weight control is monitored every 10 minutes during the first hour and every 30 minutes thereafter. Release testing includes hardness, friability by USP <1216>, content uniformity by USP <905>, and dissolution by USP <711>. The terminal product is a film-coated tablet with improved dose-to-dose mass uniformity compared with the direct compression variant.

Capsule Fill Uniformity and Shell Moisture Transfer Controls

Because low-dose capsule filling places the API at roughly 5% w/w to 6% w/w of the fill mass, content uniformity risk controls the blend sequence. The four label claims of 10 mg, 25 mg, 50 mg, and 75 mg base require exact salt quantities of 11.38 mg, 28.45 mg, 56.90 mg, and 85.35 mg. For the 10 mg strength, a fill weight of 200 mg to 220 mg places the API at approximately 5% w/w to 6% w/w. The blend is therefore prepared by staged geometric dilution. The API is first blended with an equal mass of microcrystalline cellulose for 10 minutes at 24 rpm. The mixture is doubled twice more with diluent and passed through a 0.5 mm screen between stages. The final blend contains pregelatinized starch as a filler-disintegrant and colloidal silicon dioxide as a glidant. Magnesium stearate is added at 0.5% w/w and blended for 80 to 100 revolutions to avoid over-lubrication. Encapsulation is run on an automatic dosator or tamping-pin machine at a speed that maintains fill weight variability below 2% RSD. Shell selection is based on moisture content. Gelatin shells perform acceptably when the fill has a loss on drying below 0.5% and the filling suite is maintained at 40% RH to 50% RH. HPMC shells are used when lower moisture transmission is required. In-process fill weight is checked every 15 minutes, and finished capsules are sampled under 21 CFR 211.165. Content uniformity is measured by USP <905>, dissolution by USP <711>, and microbial quality by USP <61> and USP <62>. The terminal product is an immediate-release hard capsule.

Granulation of nortriptyline hydrochloride into an oral suspension intermediate is performed when dose titration below the marketed 10 mg per 5 mL oral solution is required. The commercial oral solution provides 10 mg base per 5 mL, equivalent to 11.38 mg hydrochloride per 5 mL, but dose titration in pediatric or geriatric settings may demand smaller increments than a liquid measuring device can reliably deliver. For granules, the API is blended with a diluent such as mannitol or sucrose, and a binder solution is prepared from starch at 2% w/w to 5% w/w solids or from povidone at 1% w/w to 3% w/w. The binder is added in a high-shear granulator, and the wet mass is passed through an 8-mesh screen. Drying is performed in a fluid-bed dryer at an inlet air temperature of 40°C to 50°C until the loss on drying reaches 1.0% to 2.0%. Dried granules are screened through a 20-mesh screen, and the fraction passing a 60-mesh screen is controlled below 20% to prevent segregation. The granulation is filled into sachets or bottles with a desiccant, and the container is chosen to provide moisture protection because the dried starch binder can absorb water. Stability testing is based on ICH Q1A and photostability under ICH Q1B because nortriptyline hydrochloride is light-sensitive in solution and in low-moisture solid dispersions. Published data for a specific nortriptyline hydrochloride granule formulation is limited, so release limits for impurity profile, moisture, and dissolution must be established during development rather than adopted from harmonized tables. The terminal product is a granule for oral suspension intended for reconstitution at the point of use.

When the Hydrochloride Salt Is Dissolved for a 10 mg per 5 mL Oral Solution, pH Buffering Governs Chemical Stability

In the oral solution presentation, nortriptyline hydrochloride is present at 10 mg nortriptyline base per 5 mL, equivalent to 11.38 mg hydrochloride per 5 mL or 2.276 mg/mL. The compounding vessel is charged with approximately 80% of the final volume of purified water, and the hydrochloride salt is added under agitation at 200 rpm to 500 rpm. A buffer system such as citric acid and sodium citrate is used to hold the solution in an acidic pH range. The exact set point is product-specific and must be retained within the registered range, typically below pH 5.0 to keep the secondary amine protonated and minimize free-base insolubility. A preservative system is added, commonly sodium benzoate at 0.1% w/w to 0.2% w/w or a paraben combination, and the preservative is qualified by antimicrobial effectiveness testing under USP <51>. The bulk solution is filtered through a 0.45 µm filter before storage, and mixing continues for 30 minutes to ensure homogeneity. The solution is filled into amber glass bottles because the API contains an aromatic secondary amine structure that is susceptible to photolytic discoloration. Photostability testing is performed under ICH Q1B. Final product testing includes assay by USP <621>, pH, preservative content, and microbial limits by USP <61> and USP <62>. The terminal product is a ready-to-use oral solution, not a concentrate.

Evaluating Sterile Filtration Limits for a Secondary Amine Hydrochloride in Water for Injection

Because no USP monograph for nortriptyline hydrochloride injection exists and no licensed parenteral product is available in most major markets, the injectable route is a development-stage application rather than an established commercial dosage form. Published data for a specific parenteral formulation of this compound is limited. A sterile solution program would start with the hydrochloride salt dissolved in Water for Injection at a concentration equivalent to 1.0 mg/mL to 2.5 mg/mL nortriptyline base. Sodium chloride is added as a tonicity agent to achieve 270 mOsm/kg to 320 mOsm/kg, and pH is adjusted to 5.0 to 6.0 with dilute sodium hydroxide or hydrochloric acid, provided the adjustment does not exceed the registered pH range. Because the molecule contains a secondary amine, nitrosamine formation is a theoretical control point. Nitrite-containing excipients, processing aids, and primary packaging components must be avoided, and the formulation should be tested for nitrosamine impurities by a validated liquid chromatography–mass spectrometry method at levels consistent with ICH M7 and regional guidance. The solution is sterilized either by terminal moist heat at 121°C for 15 minutes if chemical stability permits, or by aseptic filtration through a 0.22 µm PVDF or polyethersulfone membrane followed by filter integrity release testing conducted by bubble point or diffusion flow according to the filter manufacturer’s qualified limits. The table below lists the injection-specific compliance matrix. Terminal vials are tested for sterility, endotoxins, particulate matter, and uniformity. Extractable and leachable evaluation follows USP <1663> and USP <1664>. The terminal product, if registered, would be a sterile single-dose injectable solution or lyophilized powder packaged in amber Type I borosilicate glass vials with bromobutyl rubber stoppers.